Literature DB >> 17048240

Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.

Laura M Kulik1, Bassel Atassi, Lodewijk van Holsbeeck, Tameem Souman, Robert J Lewandowski, Mary F Mulcahy, Russell D Hunter, Albert A Nemcek, Michael M Abecassis, Kenneth G Haines, Riad Salem.   

Abstract

PURPOSE: To present the clinical data of 35 patients with T3 unresectable hepatocellular carcinoma (HCC) that were treated with (90)Y with the specific intent of downstaging to resection, radiofrequency ablation (RFA) candidate, United Network for Organ Sharing (UNOS) stage T2 or liver transplantation.
MATERIALS AND METHODS: One hundred fifty patients with unresectable HCC were treated with (90)Y microspheres. Of these, 35 patients were UNOS stage T3 at the time of treatment. Patients were followed for clinical toxicities, alterations in model for end-stage-liver disease (MELD) score, tumor response, downstaging to RFA, resection, transplantation, and survival.
RESULTS: Nineteen of 34 patients (56%) were successfully downstaged from T3 to T2 following treatment. 11 of 34 (32%) patients treated were downstaged to target lesions measuring 3.0 cm or less. Twenty-three of 35 (66%) were downstaged to either T2 status, lesion < 3.0 cm (RFA candidate), or resection. Seventeen of 34 (50%) had an objective tumor response by WHO criteria. Eight patients (23%) were successfully downstaged and underwent OLT following treatment. 1, 2, and 3-year survival was 84%, 54%, and 27%, respectively. Median survival by Kaplan-Meier analysis for the entire cohort was 800 days.
CONCLUSION: These data suggest that intra-arterial (90)Y microspheres can be used as a bridge to transplantation, surgical resection, or RFA. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17048240     DOI: 10.1002/jso.20609

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  90 in total

Review 1.  Radioembolization for primary and metastatic liver cancer.

Authors:  Khairuddin Memon; Robert J Lewandowski; Laura Kulik; Ahsun Riaz; Mary F Mulcahy; Riad Salem
Journal:  Semin Radiat Oncol       Date:  2011-10       Impact factor: 5.934

2.  Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation.

Authors:  Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre; Marco Colasanti; Edoardo De Werra; Gianluca Mascianà; Daniele Ferraro; Giovanni Tortorelli; Rosa Sciuto; Pierleone Lucatelli; Giuseppe Pizzi; Ubaldo Visco-Comandini; Giovanni Vennarecci
Journal:  Hepatobiliary Surg Nutr       Date:  2017-02       Impact factor: 7.293

3.  Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis.

Authors:  Feng Xie; Jiajie Zang; Xiaojing Guo; Feng Xu; Rongxi Shen; Long Yan; Jiamei Yang; Jia He
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-18       Impact factor: 4.553

4.  Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.

Authors:  Robert J Lewandowski; Mary F Mulcahy; Laura M Kulik; Ahsun Riaz; Robert K Ryu; Talia B Baker; Saad M Ibrahim; Michael I Abecassis; Frank H Miller; Kent T Sato; Seanthan Senthilnathan; Scott A Resnick; Edward Wang; Ramona Gupta; Richard Chen; Steven B Newman; Howard B Chrisman; Albert A Nemcek; Robert L Vogelzang; Reed A Omary; Al B Benson; Riad Salem
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

5.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

Review 6.  Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma.

Authors:  Samdeep K Mouli; Laura W Goff
Journal:  Curr Treat Options Oncol       Date:  2017-10-27

7.  Value of tumor stiffness measured with MR elastography for assessment of response of hepatocellular carcinoma to locoregional therapy.

Authors:  Sonja Gordic; Jad Bou Ayache; Paul Kennedy; Cecilia Besa; Mathilde Wagner; Octavia Bane; Richard L Ehman; Edward Kim; Bachir Taouli
Journal:  Abdom Radiol (NY)       Date:  2017-06

Review 8.  Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides.

Authors:  Jean-Luc Raoul; Eveline Boucher; Yan Rolland; Etienne Garin
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-01       Impact factor: 46.802

9.  Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.

Authors:  Ahsun Riaz; Robert J Lewandowski; Laura Kulik; Robert K Ryu; Mary F Mulcahy; Talia Baker; Vanessa Gates; Ritu Nayar; Ed Wang; Frank H Miller; Kent T Sato; Reed A Omary; Michael Abecassis; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-05       Impact factor: 2.740

10.  Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis.

Authors:  M A D Vente; M Wondergem; I van der Tweel; M A A J van den Bosch; B A Zonnenberg; M G E H Lam; A D van Het Schip; J F W Nijsen
Journal:  Eur Radiol       Date:  2008-11-07       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.